AnGes

April 23, 2013
AnGes MG, Inc.

Enhancing Effect of Japanese Herbal Medicine on CIN Therapeutic Vaccine

AnGes MG, Inc. ("AnGes") announced that Dr. Kei Kawana (Obstetrics & Genecology, the University of Tokyo Hospital) reported new findings in relation to the cervical intraepithelial neoplasia (CIN) therapeutic vaccine of AnGes, in that the addition of certain types of Japanese herbal medicines considerably enhance the effect of the vaccine. AnGes considers this finding an important element in proceeding with the development of the vaccine, and will establish a right against this finding. AnGes holds the right to exclusively develop, manufacture, use, and market the therapeutic vaccine licensed from BioLeaders Corporation (announced on April 3, 2013).

Oral CIN therapeutic vaccine elicits mucosal cytotoxic T-cell responses specific for the E7 antigen of human papilloma virus (HPV), which causes cervical cancer. The animal model study indicated that the targeted mucosal E7-specific T-cell responses in intestinal mucosal tissues enhances with administration of Japanese herbal medicines in addition to the CIN therapeutic vaccine.

Antigen-specific cytotoxic T-cells selectively attack and destroy HPV-infected cells in precancerous cervical lesions. The study showed that the enhancing effect of Japanese herbal medicine was 3-fold higher than that of the CIN therapeutic vaccine alone. Enhancement was also observed in the production of interferon gamma and interleukin-2, cellular immunity-related factors.

AnGes plans to establish a right against this finding and to explore the feasibility of combination use of the CIN therapeutic vaccine and medical agents such as the abovementioned herbal medicines, which can have synergistic effects.

This trend will have no effect on business performance for the fiscal year 2013.

###

Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between

the two language versions, the original document in Japanese shall take precedence.

AnGes MG, Inc. Corporate Communications TEL: +81-3-5730-2641, FAX: +81-3-5730-2635 http://www.anges-mg.com